IRAK4 and pancreatic adenocarcinoma: IRAK4 favored survival for patients with BLCA, PAAD, SKCM, THYM, and UCEC (HR < 1, P < 0.05), but was associated with poor survival for LGG and KICH (HR > 1, P < 0.05).